Compare Boston Beer Company Inc (SAM) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Boston Beer Company Inc trades at $171.2 (market cap $1.76B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.32 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is the larger of the two by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| SAM | SLS | |
|---|---|---|
Market Cap | $1.76B | $2.27B |
Volume | 264,496 | 4,179,659 |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $15.46 |
52-Week Low | $161.08 | $1.39 |
Typical Hold Time | 59 Days | — |
Enterprise Value | $1.53B | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAM trades at $168.16, down 1.3% over the past day, with a neutral technical signal and bearish moving averages. The stock has a P/E of 22.66 and P/S of 0.94, indicating moderate valuation. Recent earnings missed expectations in Q1 and Q2 2026, but net income improved to $108.47M in 2025. The company is expanding its product portfolio with new cocktails and coolers, though volume growth remains a challenge.
The outlook is mixed: analyst consensus is a $204.44 price target with a majority hold rating, but negative net income margin and ROE highlight profitability risks. Key opportunities include brand investments and innovation, while risks involve declining volumes and cost pressures in a competitive market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
